A phase Iclinical trial identified gastrointestinal and cardiac effects as limiting dosing.[3] Two phase IIclinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.[4]
ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.[5]
^"ZD6126". NCI Drug Dictionary. U.S. National Cancer Institute.
^LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, et al. (April 2008). "Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors". Investigational New Drugs. 26 (2): 159–67. doi:10.1007/s10637-008-9112-9. PMID18219445. S2CID40419869.
^"ZD6126". ClinicalTrialsGov. U.S. National Library of Medicine.